Perspective Therapeutics (NYSE:CATX) Upgraded by Wedbush to Strong-Buy

Perspective Therapeutics (NYSE:CATX) was upgraded by investment analysts at Wedbush to a “strong-buy” rating in a research note issued on Monday, Zacks.com reports.

Several other research firms have also issued reports on CATX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Truist Financial started coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target for the company. Oppenheimer lowered their price objective on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, Bank of America assumed coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 price target for the company. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $20.71.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $12.59 on Monday. Perspective Therapeutics has a 1 year low of $2.20 and a 1 year high of $19.05. The company’s 50-day simple moving average is $13.81.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The company had revenue of $0.53 million during the quarter. As a group, research analysts forecast that Perspective Therapeutics will post -0.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. ZWJ Investment Counsel Inc. purchased a new stake in Perspective Therapeutics during the first quarter valued at $26,000. Bleakley Financial Group LLC purchased a new stake in shares of Perspective Therapeutics during the 1st quarter valued at about $40,000. Victory Capital Management Inc. bought a new position in shares of Perspective Therapeutics in the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd purchased a new position in shares of Perspective Therapeutics in the second quarter worth approximately $118,000. Finally, RIA Advisory Group LLC grew its position in Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after buying an additional 99,293 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.